Twinstrand Biosciences
Seattle, US · Delaware corporation · 2 known investors
TwinStrand develops Duplex Sequencing technology, a genomic platform for improving accuracy in clinical medicine and life sciences research applications. The company works with partners to translate genomic research into products for human health and scientific discovery.
BiotechData & InfrastructureDeep TechMedical Devices
Founders & leadership
CW
Chad WaiteDirector
JS
Jesse SalkExecutive Officer, Director, Promoter
KB
Kellie BickelExecutive Officer
MP
Michael PelliniDirector
SD
Steve DowDirector
SS
Soma SomasegarDirector
EC
Elena CantExecutive Officer
KD
Karen DabbsExecutive Officer
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$10.3MraisedJun 2023 · 9 investors · Other TechnologyRule 506(b)
▶$10.3MraisedJun 2023 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- MIKE PELLINIDirector
- JASON MYERSDirector
- KAREN DABBSExecutive Officer
- SOMA SOMASEGARDirector
- DAVID CANNERDirector
- RONNIE ANDREWSExecutive Officer
- CHAD WAITEDirector
- Offering amount
- $25.7M
- Amount sold
- $10.3M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedMay 2021 · 21 investors · Other TechnologyRule 506(b)
▶$50MraisedMay 2021 · 21 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Chad WaiteDirector
- Jesse SalkExecutive Officer, Director, Promoter
- Kellie BickelExecutive Officer
- Michael PelliniDirector
- Steve DowDirector
- Soma SomasegarDirector
- Elena CantExecutive Officer
- Karen DabbsExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.3MraisedDec 2019 · 45 investors · Other TechnologyRule 506(b)
▶$16.3MraisedDec 2019 · 45 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Jesse SalkExecutive Officer, Director, Promoter
- Chad WaiteExecutive Officer, Director
- Michele FernandesExecutive Officer
- Terry MyersonDirector
- Steve DowDirector
- Offering amount
- $16.3M
- Amount sold
- $16.3M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.2MraisedAug 2018 · 23 investors · BiotechnologyRule 506(b)
▶$1.2MraisedAug 2018 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve DowDirector
- Christopher BenoitExecutive Officer, Director
- Jesse SalkExecutive Officer, Director, Promoter
- Lawrence LoebDirector, Promoter
- Offering amount
- $4M
- Amount sold
- $1.2M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$5.3MraisedSep 2017 · 39 investors · BiotechnologyRule 506(b)
▶$5.3MraisedSep 2017 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve DowDirector
- Chad Waite, Jr.Executive Officer, Director
- Linden RhoadsDirector
- Chris IgielskiExecutive Officer, Director
- Lawrence LoebDirector, Promoter
- Jesse SalkExecutive Officer, Director, Promoter
- Offering amount
- $5.5M
- Amount sold
- $5.3M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.9MraisedJun 2016 · 18 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2016 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KrandaExecutive Officer, Director, Promoter
- Jesse SalkDirector, Promoter
- Michael SchmittDirector, Promoter
- Chad Waite, Jr.Director
- Linden RhoadsDirector
- Lawrence LoebDirector, Promoter
- Offering amount
- $2.3M
- Amount sold
- $1.9M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.